ABBV : Summary for AbbVie Inc. - Yahoo Finance

U.S. Markets open in 9 hrs 3 mins

AbbVie Inc. (ABBV)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
61.77+0.29 (+0.47%)
At close: 4:01PM EST
People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close61.48
Bid0.00 x
Ask0.00 x
Day's Range61.17 - 62.08
52 Week Range53.74 - 68.12
Avg. Volume7,239,416
Market Cap100.38B
PE Ratio (TTM)17.02
Earnings DateN/A
Dividend & Yield2.56 (4.14%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Market Realist17 hours ago

    Enbrel Strengthens Its Position in Rheumatology and Dermatology Segments

    In 2016, Enbrel’s sales totaled ~$5.5 billion, which is a year-over-year rise of around 3.2%.

  • Pfizer's Xeljanz Combo Comparable to AbbVie's Humira
    Zacks4 days ago

    Pfizer's Xeljanz Combo Comparable to AbbVie's Humira

    Pfizer, Inc. (PFE) announced top-line results from a head-to-head study comparing its rheumatoid arthritis (RA) drug Xeljanz with AbbVie, Inc.'s (ABBV) Humira.

  • PR Newswire4 days ago

    AbbVie Announces $5 Billion Increase to Stock Repurchase Program

    NORTH CHICAGO, Ill., Feb. 17, 2017 /PRNewswire/ -- The board of directors of AbbVie Inc. (ABBV) has authorized a $5 billion increase to AbbVie's existing stock repurchase program. The stock repurchase authorization permits shares to be repurchased in open market or private transactions, has no time limit and may be discontinued at any time. AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories.